Figure 1. Key: CR – complete response; DLBCL – diffuse large B-cell lymphoma; IPI – International Prognostic Index; R-CHOP – rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Table 1. Baseline demographic and clinical characteristics by post-CR treatment cohort
Table 2. Outcomes by post-CR treatment cohort
Figure 2. Key: CR – complete response. Note: Three patients receiving alternative post-CR treatments were excluded from this analysis.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
